Effect of janus kinase inhibitors and methotrexate combination on malignancy in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials
ConclusionThe adjunction of JAKi to MTX is not associated with an increased risk of malignancy when compared to MTX alone. There is no increased risk of SAE and deaths when compared to MTX alone in patients with RA.
Source: Autoimmunity Highlights - Category: Allergy & Immunology Source Type: research
More News: Allergy & Immunology | Arthritis | Autoimmune Disease | Cancer | Cancer & Oncology | Methotrexate | Rheumatoid Arthritis | Rheumatology | Skin | Skin Cancer | Statistics